AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Short-term borrowings & bank overdrafts by Quarter
Short-term borrowings & bank overdrafts ($M) ($M)
AstraZeneca Short-term borrowings & bank overdrafts: -$542M in Q2 2026, down 3.4% from a year earlier.
Latest, Q2 2026
-542
Period ended Jun 30, 2026
Change on a year earlier
-3.4%
-561 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
“|| Overdrafts and short-term borrowings | (542) | (644) | (561)”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Net Debt Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca Short-term borrowings & bank overdrafts ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/nd-st-borrowings
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.